Longeveron (NASDAQ:LGVN) Earns Buy Rating from HC Wainwright

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other analysts have also recently issued reports on LGVN. Roth Capital raised shares of Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm initiated coverage on shares of Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 target price on the stock.

Longeveron Trading Down 0.7 %

Shares of NASDAQ LGVN opened at $1.52 on Monday. The stock has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.91. Longeveron has a twelve month low of $0.77 and a twelve month high of $6.40. The stock has a market capitalization of $22.55 million, a PE ratio of -0.24 and a beta of 0.36.

Hedge Funds Weigh In On Longeveron

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp purchased a new position in Longeveron in the third quarter worth approximately $29,000. Northern Trust Corp acquired a new stake in shares of Longeveron in the 4th quarter valued at $31,000. Jane Street Group LLC purchased a new stake in shares of Longeveron during the 4th quarter worth $35,000. Virtu Financial LLC acquired a new position in shares of Longeveron during the fourth quarter worth $53,000. Finally, Geode Capital Management LLC increased its holdings in shares of Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the last quarter. 10.01% of the stock is owned by institutional investors and hedge funds.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.